Genitourinary Cancer

Alyson Moadel, PhD, director of psychosocial oncology, Albert Einstein College of Medicine, Montefiore Medical Center, discusses partner-related side effects of prostate cancer.

Matthew Galsky, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, discusses treatment for lymph node-positive bladder cancer.

Researchers have discovered that shorter, more intensive radiation treatment for patients in the early stages of prostate cancer can be performed without compromising cancer control.

The FDA granted the PD-L1 inhibitor atezolizumab (Tecentriq) an accelerated approval as a treatment for patients with locally advanced or metastatic urothelial carcinoma.

Although androgen deprivation therapy (ADT) has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether ADT causes clinically significant depression.

The US Congress passed the Agent Orange Act of 1991 to address whether exposure to herbicides, such as Agent Orange, contributed to long-term health effects in Vietnam veterans.

The FDA has approved cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.

Sumanta K. Pal, MD, City of Hope Cancer Center, discusses the great strides in kidney cancer care that have been made in the past decade.

E. David Crawford, MD, professor of radiation oncology University of Colorado Denver, discusses the potential side effects of frequently used prostate cancer treatments.

Empowering patients with prostate cancer and their caregivers through practical information and insight into the medical world to help them be better informed.

Androgen-deprivation therapy, while an effective treatment for prostate cancer, can result in side effects and a reduced quality of life.

For undiagnosed men who took regular aspirin their risk of developing a lethal form of prostate cancer was reduced by 24%, and among those already diagnosed with the disease, regular aspirin use lowered their risk of dying from it by 39%.

Based on an extension in overall survival (OS) in the CheckMate-025 trial, Opdivo (nivolumab) has been approved by the FDA for patients with metastatic renal cell carcinoma (RCC) following prior treatment with an anti-angiogenic therapy.

SonaCare Medical's Sonablate 450 ultrasound device has received de novo clearance by the FDA for ablation of prostate tissue.

Not always reported by men with prostate cancer.

The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center.

While controversial, advances in understanding how prostate cancer treatments impact the physiology of erections have led to increased interest in penile rehabilitation interventions for these patients.

Two web-based interventions that help men with prostate cancer deal with sexual dysfunction and other common side effects of treatment are demonstrating how tech tools can be successfully deployed to address the psychosocial needs of patients, their caregivers, and survivors.

A phase III trial evaluating the efficacy of nivolumab (Opdivo) for the treatment of advanced renal cell carcinoma has been stopped early after the immunotherapy agent demonstrated a survival advantage over the comparator drug, everolimus (Afinitor), in the CheckMate-025 trial.

Clinicians and the public need to be aware that being positive for BRCA mutations has consequences for men and their families, too.

Although use of robotic surgery for prostate cancer has surpassed open surgical procedures, the impact of this approach on patient quality of life has not been well-studied.

When the United States Preventive Services Task Force (USPSTF) recommended against routine PSA screening for early detection of prostate cancer in May 2012, it caused a sea change in practice patterns among primary care physicians.

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

Statin use before or after a diagnosis of lung cancer may be linked to a reduced risk of death from the disease, according to findings of a recent study which found that patients who used statins in the year before a lung cancer diagnosis had a statistically significant 12% reduction in lung cancer-specific deaths.